Ranking Invest

Chinook Therapeutics, Inc.

Segmento: Healthcare Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

Indicadores Básicos

Valor de Mercado

$ 2.71 Bi

IVR

-0.04

IVR2

-0.17

Índices de Previsibilidade

Faturamento

2.81

Lucro

1.24

Margem

1.30

Índices de Tendência

Faturamento

3.55

Lucro

-8.80

Margem

-0.89

Índices de Endividamento

DIV/PAT

-0.26

DIV/L4T

0.38

Dívida Líquida

-$ 93.16 Mi

Patrimônio Líquido

$ 357.04 Mi

L4T

-$ 243.21 Mi

MM4T

-6043.56%

Dívidas
Dividendos
Cotação: $40.39

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre